Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIMK1 | P53667 | 2/20 | 0.50 |
| ▸ | PIM1 | P11309 | 4/20 | 0.43 |
| ▸ | PIM3 | Q86V86 | 3/20 | 0.43 |
| ▸ | PIM2 | Q9P1W9 | 3/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.41 |
| ▸ | F9 | P00740 | 2/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | PI4KA | P42356 | 1/20 | 0.40 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 2/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.38 |
| ▸ | TRIM58 | Q8NG06 | 1/20 | 0.37 |
| ▸ | TNKS | O95271 | 1/20 | 0.36 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16978724 | 0.95 | LIMK1 (0.47) | LIMK1PIM1PIM3PIM2ROCK1 | |
| SCHEMBL24619638 | 0.91 | LIMK1 (0.54) | LIMK1PIM1PIM3PIM2ROCK1 | |
| SCHEMBL753398 | 0.91 | LIMK1 (0.54) | LIMK1PIM1PIM3PIM2ROCK1 | |
| SCHEMBL17037070 | 0.91 | LIMK1 (0.57) | LIMK1PIM1PIM3PIM2ROCK1 | |
| SCHEMBL16672063 | 0.89 | ESR1 (0.47) | LIMK1PIM1PIM3PIM2F9 | |
| SCHEMBL16978720 | 0.89 | LIMK1 (0.50) | LIMK1PIM1PIM3PIM2F9 | |
| SCHEMBL16672064 | 0.89 | ESR1 (0.47) | LIMK1PIM1PIM3PIM2F9 | |
| SCHEMBL25042118 | 0.89 | ESR1 (0.47) | LIMK1PIM1PIM3PIM2F9 | |
| SCHEMBL19916761 | 0.88 | LIMK1 (0.42) | LIMK1PIM1PIM3PIM2ROCK1 | |
| SCHEMBL19916732 | 0.88 | LIMK1 (0.42) | LIMK1PIM1PIM3PIM2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9187493-B2 | Heterocyclic compound and use thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2015-11-17 | — | — | US | disclosed |
| US-9187493-B2 | Heterocyclic compound and use thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2015-11-17 | — | — | US | disclosed |
| US-20150218185-A1 | Heterocyclic Compound And Use Thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2015-08-06 | — | — | US | disclosed |
| US-20150218185-A1 | Heterocyclic Compound And Use Thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2015-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150218185-A1 | Heterocyclic Compound And Use Thereof | CCNE1, CRY1, CCNE2 | LIMK1 1164/4885PIM1 2336/4885PIM3 3533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.